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Abstract
Background: Genes involved in Tourette syndrome (TS) remain largely unknown. We aimed to identify genetic factors contributing to TS in a French cohort of  
120 individuals using a combination of  hypothesis-driven and exome-sequencing approaches.
Methods: We first sequenced exons of  SLITRK1-6 and HDC in the TS cohort and subsequently sequenced the exome of  12 individuals harboring rare variants in these 
genes to find additional rare variants contributing to the disorder under the hypothesis of  oligogenic inheritance. We further screened three candidate genes (OPRK1, 
PCDH10, and NTSR2) preferentially expressed in the basal ganglia, and three additional genes involved in neurotensin and opioid signaling (OPRM1, NTS, and NTSR1), and 
compared variant frequencies in TS patients and 788 matched control individuals. We also investigated the impact of  altering the expression of  Oprk1 in zebrafish.
Results: Thirteen ultrarare missense variants of  SLITRK1-6 and HDC were identified in 12 patients. Exome sequencing in these patients revealed rare possibly 
deleterious variants in 3,041 genes, 54 of  which were preferentially expressed in the basal ganglia. Comparison of  variant frequencies altering selected candidate 
genes in TS and control individuals revealed an excess of  potentially disrupting variants in OPRK1, encoding the opioid kappa receptor, in TS patients. Accordingly, 
we show that downregulation of  the Oprk1 orthologue in zebrafish induces a hyperkinetic phenotype in early development.
Discussion: These results support a heterogeneous and complex genetic etiology of  TS, possibly involving rare variants altering the opioid pathway in some 
 individuals, which could represent a novel therapeutic target in this disorder.
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Introduction
Tourette syndrome (TS) is a neurodevelopmental disorder character-
ized by multiple involuntary motor and vocal tics that typically begin in 
childhood and have a waxing and waning course.1–3 Twin studies have 
provided compelling evidence that TS is genetically determined,4–7 but 
the nature of  the involved genetic factors, their mode of  inheritance, 
and the mechanisms by which they act remain largely unknown.
Recent studies have emphasized that the genetic architecture of  TS is 
very likely oligo- (i.e., involving a few gene loci) or poly-genic (i.e., influ-
enced by many genes as well as environmental factors) and overlaps with 
that of  frequently comorbid disorders, such as autism spectrum disor-
ders, obsessive-compulsive disorder (OCD), attention deficit hyperactiv-
ity disorder (ADHD), and depression.8–10 Main genes possibly involved in 
TS so far include NRXN1, CNTN6, CELSR3, SLITRK1, and HDC.11–22 
SLITRK1 encodes a transmembrane protein modulating neurite out-
growth belonging to a family comprising six paralogues (SLITRK1 to 
SLITRK6) in mammals.23,24 HDC encodes histidine decarboxylase, the 
enzyme catalyzing the synthesis of  histamine through decarboxylation 
of  histidine.11 Slitrk1-, Slirk5-, and Hdc-deficient mice show behavioral 
disturbances and elevated anxiety-like behaviors, further supporting the 
involvement of  these genes in neuropsychiatric disorders.25–31
In this study, we sequenced exons of  SLITRK1-6 and HDC genes and 
analyzed the exome of  12 TS patients with rare variants in these genes to 
find additional hits contributing to the disorder under the hypothesis of  
oligogenic inheritance. We focused our analysis on rare, possibly disrupt-
ing variants in genes preferentially expressed in the basal ganglia, one of  
the main brain regions of  interest in TS.32 Screening of  candidate genes 
in our TS cohort and comparison of  variant frequencies in control pop-
ulations identified OPRK1 variants as susceptibility factors for TS.
Methods
Participants
This study included 120 French individuals (92 males and 28 females, 
M/F sex ratio: 3.3) with TS syndrome recruited from the “Réseau 
National Gilles de la Tourette” (INSERM RBM 04-18; 2005–2007) and 
the “Centre de Référence National Maladies Rares Syndrome Gilles de 
la Tourette” (Pitié-Salpêtrière Hospital, Paris, France). Patient assess-
ment is described in detail elsewhere.33 Twelve patients with rare vari-
ants in SLITRK1-6 and HDC (see supplementary Table 1) from this 
cohort were identified and further analyzed by exome sequencing 
(Figure 1). One patient out of  12 (SGT-003-04) had pervasive develop-
mental disorder not otherwise specified (PDD-NOS) in addition to TS. 
A total of  788 French healthy individuals matched on sex (632 males 
and 156 females, M/F sex ratio: 4.0) were selected from the same data-
bank (DNA and cell bank of  Institut du Cerveau et de la Moelle épin-
ière [ICM]) to compare variant frequencies in NTS, OPRK1, and 
OPRM1. Genomic DNA was extracted from blood cells using standard 
phenol–chloroform procedures.
Sanger sequencing
Specific primer pairs were designed to amplify the coding exons 
and adjacent intron–exon boundaries of  SLITRK1-6 and HDC. 
The same primers were used to sequence the coding regions of  
these genes in the 120 TS patients. After exome sequencing, six 
genes were selected and sequenced by Sanger sequencing: OPRK1, 
OPRM1, PCDH10, NTS, NTSR1, and NTSR2. All primer sequences 
are provided in supplementary Table 2. Forward and reverse sequence 
reactions were performed with the Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, 
USA). G50-purified sequence products were run on an ABI 3730 
automated sequencer (PE Applied Biosystems) and data were ana-
lyzed with Seqscape v2.6 software (Applied Biosystems). In addition, 
63 variants identified by exome sequencing were confirmed by Sanger 
sequencing (supplementary Table 3). For genes with multiple 
expressed isoforms, the longest isoform was used to describe variants. 
The variant nomenclature is based on the following cDNA reference 
sequences: OPRM1: NM_001145279 (longest isoform) and 
NM_000914.4 (main isoform); OPRK1: NM_000912.3; PCDH10: 
NM_032961.1; NTS: NM_006183.4; NTSR1: NM_002531.2; 
NTSR2: NM_012344.3.
Figure 1.  Flowchart Illustrating the Strategy and Results of  this Study. 
The scheme summarized the different experimental steps and main results obtained.
Depienne C, Ciura S, Trouillard O, et al. Opioid receptor variants in Tourette syndrome
Columbia University Libraries
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org 3
Exome sequencing
We sequenced the exome of  12 patients with variants in SLITRK1-6 
and HDC (Figure 1). Genomic DNA was captured using the SureSelect 
Human All Exon 50 Mb Kit (Agilent, Santa Clara, CA, USA) followed 
by paired-end 75 bp massively parallel sequencing on a HiSeq2000-
sequencing system (Illumina, San Diego, CA), according to the manufac-
turer’s instruction and protocols,34 by Integragen SA (Evry, France). 
Image analysis and base calling were performed using Illumina Real 
Time Analysis (RTA) Pipeline version 1.8 with default parameters. 
Analysis of  exome data was based on the Illumina CASAVA1.7 pipeline, 
using the ELANDv2 alignment algorithm. Variant annotation was real-
ized with an in-house pipeline (Integragen Evry, France), consisting of  
gene annotation (RefSeq), frequencies of  the variants at the homozygous 
or heterozygous state in databases (HapMap, 1,000 genomes, exome 
variant server [EVS]) and in exomes sequenced at Integragen, and anal-
ysis of  the impact of  the variants (exonic, intronic, silent, nonsense, etc.). 
Variant filtering was performed using the Eris interface (Integragen) with 
the following parameters: (1) minor allele frequencies (MAFs) ≤0.01 (rare 
heterozygous variants) or 0.001 (homozygous variants) in dbSNP, 
Hapmap, 1,000 genomes, AVS, and a local exome database; (2) a pre-
dictable damaging impact on the gene or the protein (nonsense variants, 
variants predicted to cause a frameshift, variants altering splice sites, mis-
sense variants, and variants introducing in-frame deletions or insertions); 
(3) coverage ≥10 reads and exclusion of  ambiguous genotypes (supple-
mentary Table 3). This list was then filtered to keep genes with variants 
(same or different) in at least two TS patients (supplementary Table 4). 
These parameters allowed to detect all 13 variants previously identified 
in the HDC and SLITRK1-6 genes. For six patients, DNA from both par-
ents was available and their exome was also sequenced to investigate de 
novo variants. For one family (SGT-003), parents were included in the first 
analysis. For the five remaining families, the index case and the parents 
were resequenced independently and these data were used to validate 
variants identified in the first experiment. Exome sequencing in family 
SGT-082 revealed an unexplained incompatibility of  the paternal DNA.
Microarrays
Copy number variants (CNVs) were independently assessed in 11/12 
index cases with HDC and SLITRK1-6 variants using OmniExpress24 
microarrays (Illumina). Automated Illumina microarray experiments 
were performed according to the manufacturer’s specifications. Image 
acquisition was performed using an iScan System (Illumina, San Diego, 
CA, USA). Image analysis and automated CNV calling were performed 
using GenomeStudio v2011.1 and CNVPartition v3.1.6 with the default 
confidence threshold of  35. CNVs identified in TS patients were com-
pared to those present in the Database of  Genomic Variants (DGV), 
using Cartagenia Bench (Agilent). Variants absent from DGV, present in 
less than three individuals, or with an overlap <80% with CNVs present 
in DGV were listed (supplementary Table 5).
Pyrosequencing
To compare the frequencies of  rare variants in NTS, OPRM1, and 
OPRK1, exons and intron–exon junctions of  these genes were screened 
in 120 patients with TS and 788 healthy controls using amplicon-based 
massive parallel pyrosequencing with a Roche 454 GS Junior. A first 
polymerase chain reaction (PCR) was performed to amplify the targeted 
exons by PCR (primers in supplementary Table 2). A second PCR was 
performed to incorporate multiplex identifier and 454 adaptors, and an 
emulsion PCR was carried out according to the emPCR Amplification 
Method Manual (Roche, Basel, Switzerland). All variants previously 
identified by Sanger sequencing were also detected by pyrosequencing 
in the TS cohort.
Bioinformatic analyses
Variants identified in TS individuals were annotated using Alamut 
2.7.1 (Interactive Biosoftware, Rouen, France). This software allows 
automatic gene variant annotation including missense predictions using 
Align GVGD, SIFT, Mutation Taster and Polyphen-2. Rare variants 
correspond to variant with MAF<0.01; ultrarare variants have an 
MAF<0.001. We used the statistical overrepresentation tests from 
PANTHER 14.135 with the “GO biological process complete” option 
to look for molecular pathways and functions enriched in gene lists 
with rare variants identified by exome sequencing in TS patients 
( supplementary Tables 6 and 7).
Median Reads Per Kilobase Million (RPKM) values for each 
human gene GTEx Analysis V6p were downloaded from the Genotype-
Tissue Expression (GTEx) portal (https://www.gtexportal.org/). Genes 
preferentially expressed in the adult basal ganglia or substantia nigra 
(maximum RPKM value in caudate, nucleus accumbens, putamen, or 
substantia nigra>maximum RPKM value in other tissues/brain regions) 
were listed and ranked according to their expression in basal ganglia/
substantia nigra compared to other tissues. The final list includes 491 
transcripts with RPKM>0.5 (supplementary Table 8). We then listed 
the 64 variants present in the 12 individuals in basal ganglia-enriched 
genes ( supplementary Table 9). Gene annotation (gene function, gene 
expression, related phenotypes, or disorders in mice and humans) was 
performed using GeneALaCarte (http://www.genecards.org/cgi-
bin/Batch Queries/Batch.pl) and MGI Batch Query (http://www.
informatics.jax.org/batch).
Missense and Loss-of-function (LoF) variants present in PCDH10, 
NTS, NTSR1, NTSR2, OPRK1, and OPRM1 present in the gnomAD36 
r2.0.1 database (http://gnomad.broadinstitute.org/) were downloaded. 
In silico pathogenicity predictions calculated by PolyPhen-2 (http://
genetics.bwh. harvard.edu/pph2/) were systematically retrieved for mis-
sense variants present in gnomAD using the batch query tool (http://
genetics.bwh.harvard.edu/pph2/bgi.shtml). Possibly or probably dam-
aging predictions by Polyphen-2, which usually are the most stringent of  
all four predictions tools, were used to filter possibly damaging variants 
and compare variant frequencies (supplementary Table 11). Variant fre-
quencies were compared using exact Fisher’s tests.
Zebrafish studies
Adult and larval zebrafish (Danio rerio) were maintained in the ani-
mal platform of  Inserm Unit U1127, ICM in Paris, according to the 
National and European Guidelines for Animal Welfare. Experiments 
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were performed on wild‐type embryos from AB and TL strains. Zebrafish 
larvae were raised in embryo water: 0.6 g/L aquarium salt (Instant 
Ocean, Blacksburg, VA) in reverse osmosis water + 0.01 mg/L methy-
lene blue in a 28°C incubator. Microinjections of  0.5 nL of  solution were 
carried out at one-cell stage of  zebrafish embryos. Antisense 
Morpholino oligonucleotides (AMOs) (GeneTools Philomath, OR) 
were used to knock down the expression of  the sole orthologue of  the 
opioid receptor kappa 1 (Oprk1: NM_182886) gene in zebrafish. 
The sequence of  the ATG-targeting AMO was the following 
AAATCTGCACCACGTTGCTGTCCA that would bind to the 
 following genomic sequence in the zebrafish genome: ACAGGC 
ATCACTATTGTTTTCAAACCTTG-GGATTTTCGTCTTAAACT
ACCTGTTTAAAATTCACAACAAGACG[(ATG)GACAGCA 
ACGTGGTGCAGATTT]. The mismatch control for this AMO 
was the following (small letters scrambled to disrupt binding) 
AAATaTGaACCACaTTGCTaTCaA. To ensure the AMO specificity, 
we also utilized a splice AMO targeting the exon2–intron2 junction with 
the following sequence: AGGACAATGCTGTTTCTTACCTGAT. 
Mismatch control for the splice AMO was the following: AGcACA 
ATcCTcTTTCTTACgTcAT. All AMOs were used at a concentration of  
0.6 mM in the injection solution for a total amount of  2.5 ng of  AMO 
injected per egg. For rescue experiments, the human wild-type OPRK1 
cDNA construct was obtained from Dharmacon, Lafayette, CO, USA, 
cloned into a pCS2 plasmid, and injected alongside the AMO at a con-
centration of  75 ng/µL. Total RNA from embryos was extracted using 
the TRIzol reagent (Invitrogen, Carlsbad, CA). RNA was quantified 
using the Nanodrop 8000 (Thermo Scientific, Waltham, MA). cDNA 
was synthesized using Transcriptor Universal cDNA Master Mix (Roche) 
with the following primer pairs to detect the expression and splicing of  
the OPRK1 transcript: forward: 5′-CATCACTGCCGTTTACTCCGT 
and reverse 5′-TCATTGGTGTCCGGAAGTCC. To record global 
activity, 28 hpf  zebrafish embryos in their chorion were placed on a plas-
tic mesh, submerged in embryo water, and imaged at the frequency of  30 
fps as previously described.37 Activity parameters were quantified using 
an automatized Zebralab system (ViewPoint, France). Analysis of  vari-
ance (ANOVA) was performed using the SigmaStat software (California) 
and data were reported as significant when p<0.05.
Results
To study the contribution of  variants in HDC and SLITRK genes in 
the French TS cohort, coding exons of  SLITRK1, SLITRK5, SLITRK6 
(chromosome [chr] 13), SLITRK3 (chr3), SLITRK2, SLITRK4 (chrX), 
and HDC (chr15) were screened in 120 TS patients by Sanger sequenc-
ing (Figure 1). Seventeen rare heterozygous variants (MAF<0.01) were 
identified in 19 unrelated index probands (supplementary Table 1). 
Among these, 12 individuals carried 13 ultrarare (MAF<0.001) variants 
modifying the coding sequence (supplementary Table 1, supplementary 
Figure 1). All variants but one (HDC: c.1492A>G, p.Arg498Gly), which 
was present in an individual who also had a variant in SLITRK6 
(c.1232C>G, p.Thr411Arg), alter amino acids conserved in mammals 
(supplementary Figure 2). One of  the three SLITRK1 variants (c.1252 
A>T, p.Thr418Ser) was previously described in patients with OCD.38 
Seven variants for which inheritance could be assessed were inherited 
from asymptomatic parents, indicating that these variants, if  involved in 
the etiology of  TS, are insufficient on their own to lead to the disorder.
To find additional hits contributing to the disorders under the 
assumption of  oligogenic inheritance, we sequenced the exome of  these 
12 patients (Figure 1). We identified a total of  3,755 rare variants (mean 
number of  variants = 408 per patient; range: 342–595) altering coding 
sequences or splice sites in 3,041 genes (supplementary Table 3). A set 
of  63 variants in selected candidate genes was validated by Sanger 
sequencing in the affected subjects, confirming the presence of  all vari-
ants but one (supplementary Table 3). At least two different variants 
were identified in two or more individuals in 424 genes (supplementary 
Table 4). One individual (SGT-040-10) for whom DNA from both par-
ents was available had two de novo variants absent or present at a very low 
frequency in gnomAD: a de novo duplication (arr[hg19] 17q12(37,042,006-
37,276,683) × 3) on chr 17q12 including three genes (FBXO47, LASP1, 
PLXDC1) and a de novo missense variant (NM_005739.3: c.2327T>C, 
p.Ile776Thr) in the RASGRP1 gene (supplementary Table 5).
We used PANTHER to determine whether specific biological pro-
cesses were enriched in the 3,041 and 424 gene lists, respectively. 
Interestingly, both lists were enriched in genes involved in cell differenti-
ation, cell adhesion, cell projection organization, neurogenesis, and neu-
ron differentiation among other cellular processes (supplementary 
Tables 6 and 7). Genes involved in these pathways include NRP2 (three 
individuals), ROBO4 (two individuals), SLIT2, NTN5, RELN, RGMA, 
plexins (PLXNA1, PLXNB1), semaphorins (SEMA4F, SEMA6B: two indi-
viduals each, SEMA3B, SEMA3C, SEMA4B, SEMA5A, SEMA5B, 
SEMA6D), ephrins (EPHA1, EPHA6: two individuals each, EPHA8, 
EPHA10, EPHB4), cadherins (CDH4: three individuals, CDH20), proto-
cadherins (PCDH10), cadherin EGF LAG Seven-Pass G-type receptors 
(CELSR3: two individuals; CELSR2), and fat-like cadherins (FAT4: four 
individuals; FAT3: three individuals; FAT1; two individuals; FAT2).
We then examined variants in genes preferentially expressed in the 
basal ganglia (supplementary Table 8), corresponding to a total of  64 
variants in 54 genes (supplementary Table 9). Among these variants, 
two in PCDH10/protocadherin 10 (c.3076C>T; p.Arg1026*) and 
OPRK1/opioid receptor kappa-1 (c.787C>T; p.Arg263*) lead to a theo-
retical protein truncation. A missense variant in the neurotensin recep-
tor-2 (NTSR2, c.397C>G, p.Arg133Gly) altering a highly conserved 
amino acid (until C. elegans) was predicted to be damaging by all four 
prediction tools used.
Opioid and neurotensin signaling pathways being relevant to TS 
 etiology, we examined variants in genes encoding ligand or receptors 
independently of  their preferential expression in the brain. We 
observed rare variants possibly altering other genes involved in opioid 
(c.743C>T, p.Thr248Ile in OPRM1/opioid receptor Mu-1) and neu-
rotensin (c.423G>C, p.Lys141Asn in NTS/neurotensin, and 
c.533C>T, p.Thr178Ile in NTSR1/neurotensin receptor-1) pathways 
in three additional patients.
We then screened NTS, NTSR1, NTSR2, OPRK1, OPRM1, and 
PCDH10 by Sanger sequencing for additional variants in our TS cohort. 
Additional rare variants were identified in all six genes, including 
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PCDH10 missense variants (c.1526G>A, p.Gly509Asp and c.2411T>C, 
p.Ile804Thr) in three individuals, one frameshift (c.348del, 
p.Gln117Asnfs*5) and one missense variant (c.190C>A, p.Leu64Ile) in 
NTS in two individuals, rare variants in NTSR1 and NTSR2 in 11 and 
3 individuals each, one nonsense (c.1107C>A, p.Tyr369*) and three 
missense variants in OPRK1 (four individuals), and eight rare variants 
including a nonsense variant (c.829C>T, p.Arg277*) in OPRM1 
 (supplementary Table 10).
Comparison of  rare variant frequencies between TS cases and individ-
uals from the gnomAD database suggested that variants in OPRK1 may be 
more frequent in TS patients than in control individuals (TS: 4.2%, con-
trols: 0.8%; p = 0.003, Fisher’s exact test, Table 1, supplementary Tables 
10 and 11). To further confirm these findings, we reanalyzed TS cases and 
a control population comprising 788 individuals matched on sex from the 
same databank for variants in OPRK1 using pyrosequencing (supplemen-
tary Table 10). We also included NTS and OPRM1 in this screening based 
on the identification of  truncating variants in these genes. Comparison of  
variant frequencies in TS cases and matched controls confirmed that there 
was a significant excess of  rare variants in OPRK1 (TS: 4.2%, controls: 
0.5%; p = 0.003, Fisher’s exact test), and to a lesser extend in OPRM1 (TS: 
6.7%, controls: 2.3%; p = 0.048, Fisher’s exact test) in TS patients, while 
the difference for NTS (TS: 2.5%, controls: 1.2%; p = 0.397, Fisher’s exact 
test) was not significant (Table 1). Variants of  OPRK1 and OPRM1 in 
which inheritance could be assessed were all inherited from an asymptom-
atic parent. In two families including affected siblings, the variant was 
also present in the affected sib (supplementary Table 3, supplementary 
Figure 3). These results suggest that variants in opioid receptors could rep-
resent susceptibility factors to TS.
We next tested the functional consequences of  altering the expression 
of  the TS candidate orthologous genes during vertebrate development. 
For this, we focused on the expression of  oprk1 in zebrafish, a simple 
vertebrate model that exhibits stereotyped movements during early 
development.39 The zebrafish genome contains a single orthologue of  
the human OPRK1 gene (ensembl: oprk1 ENSDARG00000006894) with 
67% identity at the protein level. Oprk1 expression is enriched in brain 
structures of  the diencephalon and mesencephalon in adult zebrafish,40 
and is expressed during the development of  the embryo.41 To investigate 
the function of  Oprk1 during early development, we performed a knock-
down of  its expression via microinjections of  morpholino-modified 
antisense oligonucleotides (AMO) in the one-cell stage embryo. We used 
two different strategies to knock down the expression of  oprk1, targeting 
either the ATG starting codon or the splice junction exons 2/intron 2. 
Injection of  2.5 ng of  either AMOs did not result in gross morphologi-
cal defects at 28 hpf  (Figure 2A) or at later stages of  development (not 
shown) when compared with non-injected or with mismatch AMO-
injected controls. To determine the effectiveness of  the splice-modifying 
AMO, we performed reverse transcription PCR using primers flanking 
the exon 2–exon 3 junction. Microfluidic capillary electrophoresis of  
the PCR products revealed a defective splicing event in fish injected 
with the splice-blocking AMO (Figure 2B). Further, a lower amount of  
PCR product was detected in the ATG-targeting AMO injected fish, 
indicating a degradation of  the oprk1 transcript (Figure 2B).
To determine the effect of  oprk1 knockdown on the motor activity, 
we analyzed the movement of  zebrafish embryos at 28 hpf. This devel-
opmental stage marks the appearance of  the first stereotyped move-
ment, consisting of  bidirectional periodic coils inside the chorion. 
Table 1.  Comparison of  the Frequencies of  Rare Variants in Six Selected Genes in TS and Control Populations
Gene Type of  variants TS cohort (120 
individuals)
gnomAD (138,632 
individuals)
p Control individuals 
(788 individuals)
p
OPRK1* Missense/LoF (MAF<1%) 5 (4.2%) 1099 (0.8%) 0.003 4 (0.5%) 0.003
Damaging/LoF (MAF<1%) 4 (3.3%) 541 (0.4%) 0.001 3 (0.4%) 0.007
OPRM1** Missense/LoF (MAF<1%) 8 (6.7%) 8,085 (5.8%) 0.694 22 (2.3%) 0.048
Damaging/LoF (MAF<1%) 5 (4.2%) 3,786 (2.7%) 0.268 10 (1.2%) 0.037
NTS Missense/LoF (MAF<1%) 3 (2.5%) 998 (0.7%) 0.057 10 (1.2%) 0.397
Damaging/LoF (MAF<1%) 2 (1.7%) 474 (0.3%) 0.064 2 (0.25%) 0.087
NTSR1 Missense/LoF (MAF<1%) 12 (10.0%) 14,333 (10.3%) 1.000 ND
Damaging/LoF (MAF<1%) 6 (5.0%) 8,248 (5.9%) 0.847 ND
NTSR2 Missense/LoF (MAF<1%) 4 (3.3%) 3,142 (2.3%) 0.353 ND
Damaging/LoF (MAF<1%) 4 (3.3%) 1,772 (1.3%) 0.069 ND
PCDH10 Missense/LoF (MAF<1%) 4 (3.3%) 2,494 (1.8%) 0.171 ND
Damaging/LoF (MAF<1%) 3 (2.5%) 1,174 (0.8%) 0.083 ND
The details of  variants included in the comparisons appear in supplementary Tables 10 and 11. The number of  variants/individuals 
calculated from gnomAD (supplementary Table 11) assumed that rare variants correspond to one individual each. Variant frequencies 
were compared with Fisher’s exact tests. * Calculations for OPRK1 excluded Asp374Asp, which is frequent in the African population 
(longest isoform NM_001318497). ** For OPRM1, only variants in exons 3, 4, and 5 of  isoform NM_001145279, which are present in at 
least 11/19 isoforms, were taken into account.
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We quantified this type of  movement using an automated video capture 
and analysis system. As illustrated in Figure 2A, knockdown of  oprk1 was 
associated with an overall increase in activity in zebrafish. Indeed, injec-
tion of  either the ATG-targeting or the splice blocking AMO resulted in 
significantly higher total movement (Figure 2C) and frequency of  coil-
ing bursts (Figure 2D). To confirm that the hyperkinetic phenotype is 
specifically associated with a loss of  function of  oprk1, we coexpressed 
human OPRK1 together with the ATG-blocking AMO. As shown in 
Figure 2, overexpression of  OPRK1 functionally rescued the knockdown 
of  the zebrafish orthologue, as both the total activity (Figure 2C) and the 
frequency of  coiling movements (Figure 2D) were restored to control 
levels. Investigation of  the global activity of  zebrafish at later stages of  
development (48 hpf–5 dpf) revealed a gradual disappearance of  the 
hyperactivity phenotype, with no significant differences from controls 
(not shown). Thus, in zebrafish, we observed an association of  oprk1 loss 
of  function with a transient hyperkinetic phenotype at early stages of  
development.
Discussion
Genetics of  TS is both complex and heterogeneous, making the iden-
tification of  interacting variants extremely challenging. In an attempt to 
circumvent this difficulty, we focused on candidate genes enriched in 
brain structures relevant to TS pathophysiology, that is, the basal gan-
glia. Although straightforward, this approach would miss variants in 
genes potentially involved in TS-related networks dysfunction but rather 
mainly expressed in other brain regions or tissues.
The main finding of  this study is an excess of  possibly disrupting 
variants in OPRK1, the gene encoding the kappa opioid receptor (KOR) 
in patients with TS. We also detected a possible, weaker association of  
TS with rare variants in OPRM1, although these results have to be inter-
preted with caution, notably because OPRM1 is a very polymorphic 
gene, encoding many different isoforms. We also show that knockdown 
of  the oprk1 orthologue in zebrafish is associated with a hyperkinetic 
phenotype that is confined to the early stages of  development. 
Overexpression of  the human OPRK1 transcript was able to rescue the 
loss of  function of  the zebrafish orthologue, highlighting the high func-
tional conservation of  the opioid receptor kappa during evolution and 
the relevance of  its investigation in lower vertebrates. Altogether, these 
results further support the hypothesis that alteration of  opioid receptor 
kappa in vivo could lead to an early transient hyperactivity phenotype 
mimicking TS. Extending this study to the functional analysis of  vari-
ants identified in TS patients may also provide additional support for 
the potential role of  OPRK1 in TS pathogenesis.
The endogenous opioid system is composed of  three different opioid 
receptor subtypes (mu, kappa, and delta), which have different function 
and brain distribution.42 These receptors are activated upon binding 
with endogenous peptides including dynorphins, enkephalins, endor-
phins, endomorphins and nociceptin, or exogenous drugs such as mor-
phine or heroin. The opioid endogenous system, and more specifically 
the KOR system,43 is involved in both motor control and psychiatric 
conditions such as anxiety, depression, schizophrenia, and addiction.44 
Sex differences in KOR function45 might contribute to sex-dependent 
clinical manifestations or to imbalanced sex ratios existing in TS and 
many other neuropsychiatric conditions such as susceptibility to develop 
addictions and depression.
The implication of  the opioid system in pathophysiology of  TS has 
been hypothesized for more than 30 years, first based on treatment stud-
ies using opiate agonists and/or antagonists.46–50 Importantly, a post-
mortem report of  a single patient with TS showed total absence of  
dynorphin-like staining in the dorsal part of  the globus pallidus externus 
and very faint staining in the ventral pallidum.51 This case was particu-
larly interesting since it pinpointed toward underactivity of  a specific 
opioid system, the dynorphin/kappa receptor system. Very recently and 
in line with our own findings, downregulation of  OPRK1 and OPRM1 
Figure 2.  Knockdown of  the Zebrafish OPRK1 Orthologue Results in Hyperactivity during Development. (A) Activity heatmap illustrating sponta-
neous movement of  28 hpf  embryos inside the chorion during a 10 seconds period. Higher levels of  activity are evident in embryos injected with oprk1 splice-blocking 
AMO (spOPRK1) or ATG-targeting AMO (OPRK1 KD) when compared to mismatch AMO-injected embryos (Mismatch control). Expression of  human OPRK1 
transcript (hOPRK1) rescues the hyperactivity phenotype. (B) RT-PCR product of  amplification of  a region spanning exons 2 and 3 of  the zebrafish oprk1 transcript. 
Injection of  the splice-blocking AMO (spOPRK1) results in a defective splicing in this region. (C) Quantification of  the total activity of  28 hpf  zebrafish embryos. 
(D) Quantification of  the frequency of  movement bursts in the 28 hpf  embryos.
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opioid receptor gene expression in the postmortem striatum of  nine 
patients with TS was reported.52 Frequent variants in OPRK1 (rs702764) 
and OPRM1 (rs1799971) have also recently been associated with impulse 
control disorders in Parkinson disease,53,54 a finding in agreement with 
genetic variants in opioid receptor contributing to impulsivity disorders, 
a comorbidity frequently associated with TS.55
With relevance to TS, KORs are located on dopaminergic afferents 
where they reduce release and increase the reuptake of  dopamine,56 
implying that inactivation of  KORs (by OPRK1 variants, for instance) 
may increase cerebral dopamine release, especially in regions such as 
the striatum.57 This would be in line with the predominant theory that 
TS pathophysiology is associated with a dopaminergic hyperinnerva-
tion.58 Little is known about the specific function of  oprk1 during zebraf-
ish development; however, a role in the differentiation of  Pax2-positive 
neurons has been suggested,41 with implications for the correct specifica-
tion of  the dopaminergic system.
Contrary to Oprk1 knockdown in zebrafish, Oprk1-deficient mice did 
not show evidence of  hyperactivity.59 Oprk1 knockdown in zebrafish and 
Oprk1 knockout in mice cannot be strictly compared as compensation 
mechanisms are very likely different when Oprk1 is downregulated or 
completely absent during development in these distinct species. 
Furthermore, locomotor activity is usually tested in adult mice and an 
early transient hyperactive phenotype could have been easily missed. 
Furthermore, locomotor phenotypes and behaviors also depend on the 
genetic background, as observed for Oprd1-deficient mice, which mainly 
showed impulsivity on a C57Bl/6J background.60,61 However, a recent 
study has shown that triple knockout of  all three opioid receptors in 
mice is associated with hyperactivity (motor restlessness) and dopamine 
abnormalities.62
The number of  patients with opioid receptor variants in our TS 
cohort remains low (3.3–4.2% compared to 0.5–0.8% in control indi-
viduals). It is also important to note that a series of  120 individuals is 
small for case-control association studies, and that TS and control pop-
ulations have not been matched for ancestry based on genotypes. 
Therefore, it would be important to replicate these findings in larger TS 
and control cohorts. The impact of  population stratification on frequen-
cies of  variants in opioid receptors is illustrated by the OPRM1 
NM_001145279:c.397A>G, p.Asn133Asp (NM_000914.4:c.118A>G, 
p.Asn40Asp, rs1799971) variant, a common functional polymorphism 
that was shown to act as a susceptibility factor for addiction and to alter 
the response treatments targeting opioid receptors.63 This variant was 
identified in 31 TS patients (28 heterozygotes and 3 homozygotes), a 
distribution similar to that observed in our control population as well as 
in the European (non-Finnish) population of  gnomAD, suggesting that 
this polymorphism does not play a major role in TS etiology. However, 
we observed that the frequency of  the G minor allele significantly varies 
across populations (much higher in Asian populations while lower in 
Africans; supplementary Table 12). This finding might have important 
consequences when considering opioid receptors as possible therapeutic 
targets in TS or other psychiatric disorders.
KOR agonists – assuming that residual receptor function is main-
tained – might indeed be novel therapeutic options to be investigated 
in TS. However, classic KOR agonists such as U50,488 or U69,593 
used experimentally to treat drug addiction have shown dysphoric and 
psychomimetic properties. Therefore, novel molecules based on 
Salvinorin A, the active compound of  Salvia divinorum, are currently 
being developed for the treatment of  substance abuse (particularly 
cocaine) but might also prove to be useful for the treatment of  tics.64
Finally, this work has also identified rare variants in several individu-
als in additional candidate genes including PCDH10, encoding a proto-
cadherin with preferential expression in basal ganglia, possibly 
contributing to the establishment of  synaptic connections in this brain 
region; ROBO4, a gene of  the ROBO/SLIT axon guidance pathway 
previously associated with TS65; NRP2, encoding neuropilin 2, a protein 
possibly controlling axon guidance of  dopaminergic neurons66; NOS1, 
encoding the neuronal nitric oxide synthase, a gene also downregulated 
in the striatum of  TS patients52 and possibly playing a role in con-
trolling motor behavior;67 and SHANK1, in which truncating variants 
were previously associated with male-limited Asperger syndrome.68 
Two individuals also had variants in CELSR3, a gene that was recently 
recognized as a candidate gene for TS.22 The possible contribution of  
these genes to TS etiology needs to be confirmed in further studies, as 
are the nature and number of  the variants acting in concert necessary 
to lead to TS.
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